Kahn Swick & Foti, LLC has initiated securities fraud class action litigation against BellRing Brands, Inc., alleging that the company failed to disclose material information to investors regarding operational challenges. The legal action follows a significant decline in BellRing's stock price, which fell 52% after the company disclosed inventory management issues and supply disruptions with key retailers.
The lawsuit is part of a broader enforcement effort by the firm, which has simultaneously filed similar securities fraud claims against two other publicly traded companies: uniQure N.V., whose stock declined 49% following FDA approval delays, and Corcept Therapeutics, which experienced a 50% stock drop related to its own FDA regulatory setbacks. These cases center on allegations that the companies withheld critical information that would have materially affected investor decision-making.
Investors who purchased securities in BellRing Brands during the relevant period and sustained losses have until March 23, 2026 to submit lead plaintiff applications in the class action proceeding. Those interested in the litigation or seeking additional information can contact Kahn Swick & Foti, LLC for further details regarding their eligibility to participate.